New hope for advanced cancers? first human trial of ERX-315 begins

NCT ID NCT06533332

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times

Summary

This early-stage study tests the safety of a new drug called ERX-315 in 15 adults with advanced solid tumors (such as breast, ovarian, or pancreatic cancer) that have stopped responding to approved therapies. The main goal is to find safe doses and watch for side effects, not to cure the cancer. Participants must be in fairly good health otherwise.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Research SA

    RECRUITING

    Adelaide, South Australia, 5000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Icon Cancer Centre Adelaide

    RECRUITING

    Adelaide, South Australia, 5037, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Macquarie University Health

    RECRUITING

    Ryde, New South Wales, 2109, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Kinghorn Cancer Center

    RECRUITING

    Sydney, New South Wales, 2010, Australia

Conditions

Explore the condition pages connected to this study.